This is the authors' abstract. We don't add key points for this paper.
Plasmodium vivax , a significant contributor to global malaria cases, poses an escalating health burden on a substantial portion of the world's population. The increasing spread of P. vivax because of climate change underscores the development of new and rational drug-discovery approaches. The Seattle Structural Genomics Center for Infectious Diseases is taking a structure-based approach by investigating essential enzymes such as N -myristoyltransferase (NMT). P. vivax N -myristoyltransferase ( Pv NMT) is a promising target for the development of novel malaria treatments unlike current drugs, which target only the erythrocytic stages of the parasite. Here, the 1.8 Å resolution ternary structure of Pv NMT in complex with myristoyl-CoA and IMP-1088, a validated NMT inhibitor, is reported. IMP-1088 is a validated nonpeptidic inhibitor and a ternary complex structure with human NMT has previously been reported. IMP-1088 binds similarly to Pv NMT as to human NMT.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Mendez et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: